Search:

Search for text in:

separate each search
term with a space

Multiple terms:

Additional Search Filters:

clear all | select all

Conference Years:

clear all | select all

Days Within Meeting:

clear all | select all

Conferences:

Availability:

clear all | select all

Participation Type:

clear all | select all

Topic Tracks*:

clear all | select all

Organ Site Tracks*:

Showing session: reset

Intratumoral Immunotherapy: Using the Tumor as the Remedy

  • Sort by:
  • Browse by:
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4
Intratumoral Immunotherapy: Using the Tumor as the Remedy
Starting the fight in the tumor: Principles for intratumoral immunotherapy
Aurelien Marabelle
Inst. Gustave Roussy, Villejuif, France
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:15 PM
Intratumoral Immunotherapy: Using the Tumor as the Remedy
Can all cancers be treated by intratumoral immunotherapy?
Thierry de Baere
Gustave Roussy, Villejuif Cedex, France
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:15 PM
Intratumoral Immunotherapy: Using the Tumor as the Remedy
Early and late immune analysis post intratumoral TLR 9 agonist in combination with ipilimumab in patients with anti PD-1 refractory melanoma
Adi Diab
UT MD Anderson Cancer Ctr., Houston, TX, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:15 PM
Intratumoral Immunotherapy: Using the Tumor as the Remedy
If losing Batf3-DC makes anti-PD1 fail, will bringing Batf3-DC to the tumor make anti-PD1 work?
Joshua D Brody
Icahn School Of Medicine At Mount Sinai, New York, NY, United States
from AACR Annual Meeting 2019 on April 2, 2019 10:30 AM-12:15 PM
<< first | < prev page: of 1 records per page: next > | last >>
pages: 1 presentations: 1 to 4 of 4